EUVIMEDEUVIMED entdecken
Crossref

Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index

Teppei Hagino iD, Marina Onda, Hidehisa Saeki iD, Eita Fujimoto, Naoko Kanda iD

The Journal of Dermatology · 2025-04 · 52 (4) · 663-671

DOI: 10.1111/1346-8138.17617 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 28.01.2025. Verfasst von Teppei Hagino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Psoriasis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long‐term real‐world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study aimed to evaluate 52‐week real‐world effectiveness of deucravacitinib in psoriasis patients, stratified by age (≥65 years vs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisProtein Kinase InhibitorsHumansMaleFemaleBody Mass IndexMiddle AgedAgedAdultAge FactorsProspective StudiesTreatment OutcomeSeverity of Illness IndexYoung AdultAdolescentJapanAged, 80 and over

Stichwörter der Autor:innen

body mass indexdeucravacitinibelderlypsoriasistyrosine kinase 2

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino, Hidehisa Saeki, Naoko Kanda

Zitieren

APA

Hagino, T., Onda, M., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index. The Journal of Dermatology, 52(4), 663-671. https://doi.org/10.1111/1346-8138.17617

Vancouver

Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index. The Journal of Dermatology. 2025;52(4):663-671. doi:10.1111/1346-8138.17617

BibTeX
@article{Hagino2025,
  author = {Hagino, Teppei and Onda, Marina and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {4},
  pages = {663--671},
  doi = {10.1111/1346-8138.17617}
}
Kostenlos starten →